Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 5/20 | 0.62 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.57 |
| ▸ | DRD3 | P35462 | 5/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.51 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.51 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104063 | 0.89 | ENPP2 (0.62) | AKR1C3ENPP2DRD3HRH4KCNH2 | |
| SCHEMBL109667 | 0.85 | ENPP2 (0.61) | ENPP2KCNH2KMT2AGRIN2DGRIN3B | |
| SCHEMBL105075 | 0.81 | ENPP2 (0.58) | ENPP2KCNH2KMT2AGRIN2DGRIN3B | |
| SCHEMBL3041478 | 0.81 | ENPP2 (0.72) | ENPP2KCNH2KMT2AGRIN2DGRIN3B | |
| SCHEMBL2548653 | 0.80 | ENPP2 (0.66) | ENPP2KCNH2MEN1KMT2AGRIN2D | |
| SCHEMBL103855 | 0.80 | ENPP2 (0.64) | ENPP2DRD3KCNH2KMT2AGRIN2D | |
| SCHEMBL105122 | 0.80 | ENPP2 (0.59) | ENPP2DRD3KCNH2KMT2AGRIN2D | |
| SCHEMBL172076 | 0.80 | ENPP2 (0.61) | ENPP2KCNH2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL3053030 | 0.79 | ENPP2 (0.83) | ENPP2KCNH2KMT2AGRIN2DGRIN3B | |
| SCHEMBL13137764 | 0.78 | ENPP2 (0.59) | ENPP2KCNH2GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791111-B2 | Piperidine and piperazine derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | claimed |
| EP-2426106-B1 | Piperidine and Piperazine derivatives for the treatment of tumours | MERCK PATENT GMBH (DE) | 2013-07-31 | — | — | EP | claimed |
| EP-2426106-A1 | Piperidine and Piperazine derivatives for the treatment of tumours | Merck Patent GmbH (DE) | 2012-03-07 | — | — | EP | claimed |
| US-20100222341-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HARTUNG (DE) | 2010-09-02 | — | — | US | claimed |
| EP-2193118-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES FOR TREATING TUMOURS | Merck Patent GmbH (DE) | 2010-06-09 | — | — | EP | claimed |
| WO-2009046841-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES FOR TREATING TUMOURS | MERCK PATENT GMBH (DE) | 2009-04-16 | — | — | WO | claimed |
| US-8791111-B2 | Piperidine and piperazine derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791111-B2 | Piperidine and piperazine derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8754097-B2 | Piperidine and piperazine derivatives | MERCK PATENT GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| US-8754097-B2 | Piperidine and piperazine derivatives | MERCK PATENT GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| EP-2426106-B1 | Piperidine and Piperazine derivatives for the treatment of tumours | MERCK PATENT GMBH (DE) | 2013-07-31 | — | — | EP | disclosed |
| EP-2426106-B1 | Piperidine and Piperazine derivatives for the treatment of tumours | MERCK PATENT GMBH (DE) | 2013-07-31 | — | — | EP | disclosed |
| US-20120316162-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| US-20120316162-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| EP-2426106-A1 | Piperidine and Piperazine derivatives for the treatment of tumours | Merck Patent GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| EP-2426106-A1 | Piperidine and Piperazine derivatives for the treatment of tumours | Merck Patent GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-20100222341-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HARTUNG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222341-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HARTUNG (DE) | 2010-09-02 | — | — | US | disclosed |
| WO-2009046841-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES FOR TREATING TUMOURS | MERCK PATENT GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316162-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | CCND2, CCND1, TPD52L2 | AKR1C3 2836/4885ENPP2 3706/4885DRD3 27/4885 |
| US-20100222341-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | CCND2, CCND1, TPD52L2 | AKR1C3 2836/4885ENPP2 3706/4885DRD3 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.